Investor Presentaiton slide image

Investor Presentaiton

Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma alnuctamab GPRC5D iber/mezi KarMMa-21: Strong data supports advancing Abecma into Phase 3 KarMMa-9 study Response, % 100% 80% Overall Response Rate ORR, 87.1% ISCR ■CR ■ VGPR PR 48.4% 60% CR, 74.2% 40% 25.8% 20% 0% 9.7% 3.2% n=31 PFS, % 100- 90- 80 70- 60- 50- 40- 30- 8 8 8 8 8 8 8 8 Progression-Free Survival Safety Grade ≥3 n=31 90.1% (SE: 5.43) 83.1% (SE: 6.89) H CRS 0 iiNT 3.2% Infections 12.9% 20- 10- All patients N=31 Number of events n=6 Median: 30.7 months (95% CI; NE, NE) 0. Manageable tolerability profile 0 -2 T T T T T T T T 4 6 8 10 12 14 16 18 20 22 24 26 28 30 8- - 32 with low rates of Gr≥3 Time, months NT and infections and At risk 31 31 29 29 29 29 27 27 27 26 26 26 22 15 9 3 0 no Gr≥3 CRS KarMMa-2 Cohort 2c studied Abecma in patients with clinical high-risk MM due to inadequate response (<VGPR) to frontline ASCT ll Bristol Myers Squibb™ 1. Dhodapkar M, et al. ASH 2022 [Presentation #3314]. Not for Product Promotional Use 83
View entire presentation